Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628270 | 0.83 | ALDH1A1 (0.43) | ESR1ESR2CYP1A2ALDH1A1MAPT | |
| SCHEMBL6948594 | 0.81 | PDGFRB (0.53) | CYP1A2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL7914703 | 0.79 | PDGFRB (0.50) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL523809 | 0.75 | RAB9A (0.44) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL7374427 | 0.75 | ADORA2A (0.41) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL9089858 | 0.75 | PDGFRB (0.39) | CYP1A2CYP11B2ALDH1A1MAPTHPGD | |
| SCHEMBL1385432 | 0.73 | ALDH1A1 (0.42) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL4722008 | 0.71 | ALDH1A1 (0.39) | ESR1ESR2ALDH1A1MAPTHPGD | |
| SCHEMBL2278930 | 0.70 | NPC1 (0.51) | ALDH1A1MAPTHPGDGLAACHE | |
| SCHEMBL2320187 | 0.70 | KDM4E (0.47) | CYP1A2ALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION | 2015-05-07 | — | — | US | disclosed |
| US-8946262-B2 | Methods of preventing and treating gastrointestinal dysfunction | ADOLOR CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8404693-B2 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110144108-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| US-7884102-B2 | opioid receptors antagonists such as 3-(3R,4R-dimethyl-piperidin-4-yl)-benzoic acid, used as analgesics or for the treatment of gastrointestinal disorders or side effect associated with an opioids | ADOLOR CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080306071-A1 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-7381721-B2 | Substituted piperidine compounds | ADOLOR CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060211733-A1 | Methods of preventing and treating opioid bowel dysfunction | ADOLOR CORPORATION (US) | 2006-09-21 | — | — | US | disclosed |
| WO-2006096577-A2 | METHODS OF PREVENTING AND TREATING OPIOID BOWEL DYSFUNCTION | ADOLOR CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20050148630-A1 | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| WO-2005056011-A1 | METHODS OF PREVENTING AND TREATING NON-OPIOID INDUCED GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005055953-A2 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | MERCK SHARP & DOHME LLC | 2005-06-09 | — | — | US | disclosed |
| WO-2004082623-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS | ADOLOR CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186135-A1 | Substituted piperidine compounds | CUBIST PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186135-A1 | Substituted piperidine compounds | OPRK1, OPRD1, OPRM1 | GSTP1 1734/4885ESR1 1021/4885ESR2 191/4885 |
| US-20060211733-A1 | Methods of preventing and treating opioid bowel dysfunction | OPRK1, SLC10A2, SI | GSTP1 80/4885ESR1 4861/4885ESR2 4543/4885 |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | VIP, FABP2, SI | GSTP1 16/4885ESR1 4548/4885ESR2 2949/4885 |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | PNMT, VIP, PREP | GSTP1 25/4885ESR1 3134/4885ESR2 2076/4885 |
| US-20080306071-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRK1, OPRD1 | GSTP1 1760/4885ESR1 1174/4885ESR2 317/4885 |
| US-20050148630-A1 | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction | SLC10A2, OPRK1, FABP2 | GSTP1 74/4885ESR1 4850/4885ESR2 4240/4885 |
| US-20110144108-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE | OPRM1, OPRK1, OPRD1 | GSTP1 1760/4885ESR1 1174/4885ESR2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.